Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586106 | 0.82 | CTSL (0.33) | CTSLCTSSCTSK | |
| SCHEMBL4846506 | 0.82 | TAAR1 (0.38) | CTSLCTSSCTSKRIPK1CES2 | |
| SCHEMBL8232131 | 0.80 | CTSS (0.36) | CTSLCTSSCTSKP2RX7 | |
| SCHEMBL17369449 | 0.79 | RIPK1 (0.32) | RIPK1CES2CES1 | |
| SCHEMBL6864278 | 0.78 | CTSL (0.39) | CTSLCTSSCTSKRIPK1CES2 | |
| SCHEMBL27828899 | 0.78 | MEP1B (0.49) | CTSLCTSSCTSK | |
| SCHEMBL1569012 | 0.77 | IDO1 (0.34) | CTSLCTSSCTSK | |
| SCHEMBL4846958 | 0.77 | CTSL (0.34) | CTSLCTSSCTSKCES2CES1 | |
| SCHEMBL10862600 | 0.76 | — | — | |
| SCHEMBL17369450 | 0.76 | RIPK1 (0.33) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| EP-1286975-B1 | BICLYCLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6794402-B2 | Bicyclic cyclohexylamines and their use as NMDA receptor antagonists | WARNER-LAMBERT COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-20030236252-A1 | Bicyclic cyclohexylamines and their use as nmda receptor antagonists | NIKAM SHAM SHRIDHAR (US) | 2003-12-25 | — | — | US | disclosed |
| EP-1286975-A1 | BICLYCLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001092239-A1 | BICICLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTOGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236252-A1 | Bicyclic cyclohexylamines and their use as nmda receptor antagonists | GRIN1, GRIN2C, GRIN2A | CTSL 2757/4885CTSS 1970/4885CTSK 2635/4885 |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | CTSL 700/4885CTSS 1119/4885CTSK 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.